Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples

Mostrar otras versiones (1)

In response to the SARS-CoV-2 pandemic many vaccines have been developed and evaluated in human clinical trials. The humoral immune response magnitude, composition and efficacy of neutralizing SARS-CoV-2 are essential endpoints for these trials. Robust assays that are reproducibly precise, linear, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Larsen, Sasha E., Berube, Bryan J., Pecor, Tiffany, Cross, Evan, Brown, Bryan P., Williams, Brittany, Johnson, Emma, Qu, Pingping, Carter, Lauren, Wrenn, Samuel, Kepl, Elizabeth, Sydeman, Claire, King, Neil P., Baldwin, Susan L., Coler, Rhea N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259906/
https://www.ncbi.nlm.nih.gov/pubmed/34230930
http://dx.doi.org/10.1101/2021.07.02.450915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259906/
https://www.ncbi.nlm.nih.gov/pubmed/34230930
http://dx.doi.org/10.1101/2021.07.02.450915

Ejemplares similares